The Application Status of Adjuvant Drugs in Our Country and the Management Countermeasures Study
HAN Shuang1, ZHONG Min-tao1,2, LI Jin1, ZHEN Jian-cun1*
1.Department of Pharmacy, Beijng Jishuitan Hospital, Beijing 100035, China; 2.Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Science, Peking University, Beijing 100191, China
Abstract��OBJECTIVE To know the current application status of the adjuvant drugs in our country, and preliminary explore the management measures of adjuvant drugs. METHODS Through searching, reading, and summarizing the relevant content and literature, the application status of adjuvant drugs in China and the global demand for rationalization of drug use were reviewed. A few questionnaires that associated with adjuvant drugs were designed by Delphi method to investigate the medicine experts nationwide and to explore the management countermeasures of adjuvant drugs. RESULTS The survey showed that 98% of medical institutions existing adjuvant drugs use of unreasonable/no specification. The medicine experts believe that there are unreasonable usages such as traditional Chinese medicine injections, cancer drugs except for chemotherapy drugs, etc. The unified management of adjuvant drugs application should determined by the state. CONCLUSION The excessive use of adjuvant drugs ubiquitous in our country. Key monitoring varieties directory of adjuvant drugs and the limit to the drugs�� use indicators to evaluate the rationality of drug use should be set. And there can be a special review team to review the use of adjuvant at regular intervals in order to standardize the clinical application of adjuvant drugs.
��ˬ, ������, ���, �罡��. �ҹ�������ҩӦ����״������Բ߳�̽[J]. �й�ҩѧ��־, 2016, 51(8): 678-682.
HAN Shuang, ZHONG Min-tao, LI Jin, ZHEN Jian-cun. The Application Status of Adjuvant Drugs in Our Country and the Management Countermeasures Study. Chinese Pharmaceutical Journal, 2016, 51(8): 678-682.
LAI Y J. Discussion on the value of adjuvant drug in clinical drug treatment[J]. Guide China Med(�й�ҽҩָ��),2014,12(13):389-390.
[2]
WHO. The Pursuit of Responsible Use of Medicines: Sharing and Learning from Country Experiences [EB/OL]. [2015-10] Geneva,2012, http://www. who. int/medicines/publications/responsible_use/en/
[3]
General Office of the State Council. Guiding opinions of the general office of the State Council on improving the work of centralized procurement of drugs in public hospitals[EB/OL]. 2015 [2015-10-21]. http://www. gov. cn/zhengce/content/2015-02/28/content_9502. htm
[4]
SUN D K. Discussion on the management mode of the use of adjuvant medicine in hospital[J]. Herald Med(ҽҩ����), 2014,33 (1): 128-129.
[5]
LIANG A H, YI Y, ZHANG Y S, et al. Pseudoallergic reactions of traditional Chinese medicine injections and the approaches for risk prevention and control [J]. Chin Pharm J(�й�ҩѧ��־),2015,50(15):1301-1308.
[6]
FEI R Q. Study on incidence rate and influencing factors of adverse drug reaction of traditional Chinese medicine injection[D]. Hunan: Central and Southern University, 2013.
[7]
ZHOU H M, LI Y P, ZHANG M H,et al. Current situation and countermeasures of adverse drug reaction of traditional Chinese medicine injection[J]. Manage Tradit Chin Med(��ҽҩ������־),2015, 23(16): 88-89.
[8]
ZHANG H N, XU J. Traditional Chinese medicine injection adverse reaction on the causes and countermeasures[J]. J Pract Tradit Chin Med(ʵ����ҽ�ڿ���־),2014,28(12): 145-147.
[9]
TANG J, WANG G J. The adverse reactions analysis of TCM injections[J]. Chin J Clin Rat Drug Use(�ٴ�������ҩ),2015,8(2A): 38-39.
[10]
SHEN B, ZHOU Y H. Analysis and disscussion of the adverse drug reactions of 127 cases induced by traditional Chinese medicine injections[J]. Chin J Tradit Chin Med Pharm(�й���ҽҩ��־),2015,30 (2): 428-431.
[11]
WANG D, CHENG G. Analysis on the annual data of adverse drug reaction monitoring[J]. Chin J Pharmacoepidemiol(ҩ�ﾯ���������ҩ),2013,22 (5):238-241.
[12]
LI W Y. Clinical observation of the effect of thrombus injection in treating angina pectoris of coronary heart disease[J]. Chin Foreign Med Res(����ҽѧ�о�),2015,13(3):32-33.
[13]
SHEN H B, WENG J. Clinical efficacy of Xueshuantong Injection in patients with acute ischemic cerebrovascular disease[J]. China Mod Doc(�й��ִ�ҽ��),2015,53(12):71-77.
[14]
ZHEN J C, CHEN Z G,CHANG Z R,et al. Comparative study on quality of Xueshuantong Injection produced by different manufactures[J]. Chin Pharm J(�й�ҩѧ��־),2001,36(12):847-850.
[15]
China Health Statistics Yearbook 2013[S]. 2013:162-324.
[16]
LIU X L, WANG H F. Investigation and analysis of 180 cases of patients with anti-tumor drugs [J]. Herald Med(ҽҩ����),2013,8(32):261-262.
[17]
GU H J, FENG P, NI M X. Analysis of clinical pharmacists participating in the intervention effect of anti cancer drugs[J]. Shanxi Med J(ɽ��ҽҩ), 2015,44(1):56-58.
[18]
JIA L H, ZHAO Z M, JIA N N, et al. Participation of clinical pharmacists in medical order check and effect analysis of anti-tumor adjuvant medication[J]. J China Pharm(�й�ҩ��),2013,24(39):3739-3742.
[19]
SHAO Y, WU G S. Analysis of anti-tumor drugs in cancer hospital[J]. J Mod Oncol(�ִ�����ҽѧ), 2007,15(9): 1333-1335.
[20]
WANG W L, ZHU M, GUO D H. Off-label and off-NCCN guidelines uses of antineoplastic drugs in China[J]. Iranian J Publ Health, 2013,42(5):472-479.
[21]
Medical management office��2010��191, Notice of the general office of the Ministry of health on printing and distributing the guidelines for the standardized diagnosis and treatment of common tumor in the city and county level hospitals[EB/OL],2010. http://www. nhfpc. gov. cn/yzygj/s3590/201012/325fdbaf4f46402680518dab22665760. shtml
[22]
ZHEN J C. Analysis of the use of anti-tumor drugs in Beijing medical insurance in 2011-2013[J]. Med Insurance Beijing(����ҽ��),2014,12(suppl):92-97.
[23]
WEN Y, YANG T Y, WAN R R, et al. The biological function and clinical application of thymosin[J]. Seek Med Ask Med(��ҽ��ҩ),2013,11(2):479-506.
[24]
LI A H, YU Y H. A report of the clinical application of thymosin[J]. J Pract Med Tech(ʵ��ҽ����־),2005,12(2):527-528.
[25]
XIE H L, LING Y W, LIU L. The observation of thymosin injection in the treatment of allergic rhinitis with double inferior turbinate[J]. Pract Clin Med(ʵ���ٴ�ҽѧ),2009,10(4):84-87.
[26]
JI M X, SI X S, HE J X, et al. Efficacy of thymosin-�� 1 for patients with severe pneumonia[J]. Zhejiang Med J(�㽭ҽѧ),2015,37(9):738-740.
[27]
LIU C B, LV S H, ZHANG X Z,et al. Progress in the role of thymosin ��4 in heart injury repair[J]. Chin J Clin(Electronic Edition)(�л��ٴ�ҽʦ), 2014,8(1):141-144.
[28]
YAN L W. A Meta analysis of the effect and safety of monosialo four hexose ganglioside in the treatment of Parkinson's disease[D]. Guangxi: Guangxi Medical University,2014.
[29]
XU X Z, TIAN F Z, PU D X, et al. Time and effect of domestic use of the nerve to improve the clinical symptoms in patients with Parkinson's disease: A retrospective analysis of 6 344 cases with multiple regions and multiple centers[J]. Chin J Tissue Engineering Res(�й���֯�������ٴ�����),2007,11(4):682-684.
[30]
WU B, LI L. The clinical analysis of 80 cases of GM-1 in the treatment of diabetic peripheral neuropathy[J]. Chin J Geront(�й�����ѧ),2011,31(5): 885-886.
[31]
ZHANG C G. GM-1 Combined with ganciclovir in the treatment of herpes zoster neuralgia with clinical observation[J]. Chin J Mod Drug Appl(�й��ִ�ҩ��Ӧ��), 2015,9 (8): 98-99.
[32]
RUAN C J. Effect of 60 cases of acute idiopathic facial palsy treated with seven aescinate combined with GM-1[J]. Chin J Pract Nervous Diseases(�й�ʵ������), 2014,17 (16): 98-99.
[33]
HE H J. Adjuvant drugs cannot be overwhelming[N]. Med Economic News(ҽҩ��Ӫ��), 2013-06-12(007).
[34]
WHO. Health systems financing: the path to universal coverage[EB/OL]. Geneva,World health report 2010. http://www. who. int/whr/2010/zh/
[34]
CHISHOLM D, EVANS D B. Improving health system efficiency as a means of moving towards universal coverage[EB/OL]. Geneva,World health report 2010 background paper, no. 28 http://www. who. int/healthsystems/topics/financing/healthreport/whr_background/en/ .
[36]
HOLLOWAY K, DIJK E. Rational use of medicines. In: The world medicines situation[EB/OL]. Geneva, World Health Organization, 2010 http://dosei. who. int/.
[37]
BUSFIELD J. Assessing the overuse of medicines[J]. Soc Sci Med, 2015,131: 199-206.
[38]
ZHANG B, WU J R, CHEN Y X, et al. Investigation of principles and ideas of variety selection for intensive safety monitoring of traditional Chinese medicine[J]. Chin J Pharmacoepidemiol(ҩ�����в�),2008,17(5):298-301.
[39]
YE Q Q. Application status and rationality evaluation of immune enhancing agent in a hospital[D]. Changsha: Central South University, 2013.
[40]
LIU X J, WEI S Y, WU Y P, et al. Study on comprehensive evaluation index system of hospital drug treatment quality[J]. Chin Hosp Pharm J(�й�ҽԺҩѧ),2005,25(5):462-463.
2016, Vol. 51 
